Press Releases
LAGOS, Nigeria, June 2, 2024 /PRNewswire/ -- The Federal Government through the Nigeria Data Protection Commission (NDPC) has granted a licence to the Institute of Information Management (IIM) to conduct examinations and certify data protection professionals for global competitiveness.
The National Commissioner of NDPC, Dr. Vincent Olatunji, who said... (continue reading...)
- Results of survey will be presented by Adrian Dobs, M.D., Professor of Medicine and Oncology, The Johns Hopkins School of Medicine, and Sandeep Dhindsa, M.B.B.S., Director of Division of Endocrinology, Diabetes and Metabolism, St. Louis University School of Medicine, at ENDO 2024 in Boston on June 2.
BUFFALO GROVE, Ill., June 2, 2024 /PRNewswire/ -- Tolmar Inc., a fully integrated pharmaceutical company, today announced results from a landmark survey of more than... (continue reading...)
CHICAGO--(BUSINESS WIRE)-- Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an add-on to the company’s xT or xR next-generation... (continue reading...)
NEW YORK, NY / ACCESSWIRE / June 2, 2024 / Today at Computex, Hour One's groundbreaking AI Avatar technology was showcased as part of NVIDIA's keynote. For the address, Hour One created a lifelike avatar of NVIDIA founder and CEO Jensen Huang that is capable of creating messages in multiple languages with a cinematic level of realism. This demonstrates the incredible potential of combining generative AI technologies, built on NVIDIA accelerated computing, to push the... (continue reading...)
Red Kale Medley
FELLSMERE, FL / ACCESSWIRE / June 2, 2024 / B&W Quality Growers, the world's largest grower of watercress, is proud to announce the launch of its latest innovation in premium leafy greens: the Red Kale Medley. This new blend is expertly crafted for the foodservice industry and features a nutritious and vibrant mix of baby red and green kale, complemented by B&W's signature watercress.
Red Kale Medley is designed to meet the increasing demand for versatile,... (continue reading...)
More Press Releases
View Older Stories-
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
-
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
-
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan
-
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines
-
Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse
-
Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-alpha-ADC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs
-
Computer Industry Joins NVIDIA to Build AI Factories and Data Centers for the Next Industrial Revolution
-
NVIDIA Supercharges Ethernet Networking for Generative AI
-
Trend Micro to Secure AI-Enabled Private Data Centers Worldwide
-
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
-
Vention to democratize industrial automation using NVIDIA AI technologies
-
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
-
GDRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
-
NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers
-
NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars
-
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
-
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lin
-
OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma
-
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the Unit
-
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
-
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
-
William Miller Spearheads Launch of Pioneering OkayCoin Staking Protocol
-
CryptoHeap Launches Comprehensive Strategy for Crypto Staking Amidst Market Fluctuations
-
RentFinder.ai Sets New Standards in Rental Estimates, Achieves 250% Surge in Usage
-
Fast Guard Service Releases Guide to Choosing the Best Fire Watch Service
-
June Joy at Juicy Stakes Casino
-
Accelerate Your Establishment Forward By Implementing These Simple Corporate Hacks
-
Exploring The Main Aspects To Consider When Eradicating Pesky Pests From Your Home
-
Sunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
-
Top 10 Compelling Reasons Why Your Kids Should Have Regular School Physicals
-
Odyssey Capital participated in the Washington D.C. Blockchain Summit, proposing the establishment of a Global Special Assets Alliance Fund initiative.
-
Are Ruby Gemstones Worth Investing In?
-
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
-
Capsucup: Where Quality and Sustainability Meet in Italian Espresso
-
Leading Contractor Marketing Agency Webrunner Media Broadens Service Portfolio
-
Xfive Recognized as a Clutch Global Leader for Spring 2024
-
ePac Flexible Packaging Sets Strategy for Continued Double-Digit Growth
-
Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
-
Eyes Defined Introduces 3D Images to Revolutionize Eyelid Surgery Planning
-
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
-
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
-
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
-
OPPO Scores Unforgettable Experiences with Global Brand Ambassador Kaka' at the UEFA Champions League Final 2024
-
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
-
OPPO Scores Unforgettable Experiences with Global Brand Ambassador Kaká at the UEFA Champions League Final 2024
-
Heineken® Celebrates Thousands of ‘Real Hardcore Fans’ by Helping Them Take Part in the UEFA Champions League Final Trophy Celebrations For The First Time Ever
-
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
-
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting